Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Levothyroxine | Euthyrox | 4.4 Special warnings and precautions for use 4.5 Interaction with other medicinal products and other forms of interaction | Interferences with laboratory test: Biotin may interfere with thyroid immunoassays that are based on a biotin/streptavidin interaction, leading to either falsely decreased or falsely increased test results.The risk of interference increases with higher doses of biotin. When interpreting results of laboratory tests, possible biotin interference has to be taken into consideration, especially if a lack of coherence with the clinical presentation is observed. For patients taking biotin-containing products, laboratory personnel should be informed when a thyroid function test is requested. Alternative tests not susceptible to biotin interference should be used, if available . Interferences with laboratory test: Biotin may interfere with thyroid immunoassays that are based on a biotin/streptavidin interaction, leading to either falsely decreased or falsely increased test results | Nov,2022 |
| Gabapentin | Neurontin | 4.6 Fertility, pregnancy and lactation | Neonatal withdrawal syndrome | Nov,2022 |
| Durvalumab | Imfinzi | 4.8. Undesirable effects | Myelitis transverse | Nov,2022 |
| Elasomeran (COVID-19 mRNA vaccine ) | Spikevax | 4.8. Undesirable effects | Heavy menstrual bleeding | Nov,2022 |
| Tozinameran (COVID-19 mRNA vaccine ) | Comirnaty | 4.8. Undesirable effects | Heavy menstrual bleeding | Nov,2022 |
| Dorzolamide | Trusopt | 4.8 Undesirable effects | Tachycardia, Hypertension | Nov,2022 |